Pemvidutide is a dual GLP-1 and glucagon receptor agonist that was tested in a phase 2b clinical trial called IMPACT for the treatment of metabolic dysfunction steatohepatitis (MASH) with fibrosis.[1][5] The study included 212 patients who received weekly pemvidutide at doses of 1.2 mg or 1.8 mg or placebo for 24 weeks.[4][5] The primary goal was to achieve resolution of MASH without worsening liver fibrosis.[5] Pemvidutide met this primary endpoint, with 59.1% of 1.2 mg and 52.1% of 1.8 mg patients achieving MASH resolution without worsening fibrosis, compared to 19.1% in the placebo group.[1][2][5] The drug was well tolerated with few discontinuations due to adverse effects.[1] An AI analysis showed that 30.6% of patients on the 1.8 mg dose achieved a reduction in fibrosis of 60% or more compared to 8.2% in the placebo group.[2][4] Altimmune plans to meet with the FDA in the fourth quarter of 2025 to move to a Phase 3 study.[4]